Finding weaknesses in ovarian cancer cells that survive treatment
Identifying vulnerabilities of ovarian cancer persister cells through integrated single-cell analyses
['FUNDING_OTHER'] · HARVARD MEDICAL SCHOOL · NIH-11221427
This study is looking at how to better target stubborn ovarian cancer cells that stick around after treatment, with the hope of finding new ways to prevent the cancer from coming back and helping patients have better outcomes.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HARVARD MEDICAL SCHOOL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11221427 on ClinicalTrials.gov |
What this research studies
This research investigates how ovarian cancer cells that persist after treatment can be targeted to prevent recurrence. By using advanced imaging techniques, the study aims to understand the unique behaviors and vulnerabilities of these residual cancer cells. The approach focuses on analyzing the metabolic and vascular changes that occur in these cells, which may provide new targets for therapy. Patients may benefit from insights that could lead to more effective treatments and improved outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been treated for ovarian cancer and are at risk of recurrence.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the chances of ovarian cancer recurrence.
How similar studies have performed: Other research has shown promise in targeting residual cancer cells, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
BOSTON, UNITED STATES
- HARVARD MEDICAL SCHOOL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUNASSEE, ENAKSHI D. — HARVARD MEDICAL SCHOOL
- Study coordinator: SUNASSEE, ENAKSHI D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer research